Brief: Repare Therapeutics Says Fast Track Designation Granted By FDA For Combination Treatment For Platinum-Resistant Ovarian Cancer
04/06/2024 21:40
June 4 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS ANNOUNCES FAST TRACK DESIGNATION
GRANTED BY
THE FDA FOR LUNRESERTIB IN COMBINATION WITH CAMONSERTIB FOR THE
TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER
Source text for Eikon: ID:nBw1T3Dqca
Further company coverage: RPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln